The Analyst Landscape: 4 Takes On Hologic

In the preceding three months, 4 analysts have released ratings for Hologic HOLX, presenting a wide array of perspectives from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $88.0, a high estimate of $95.00, and a low estimate of $79.00. This upward trend is apparent, with the current average reflecting a 7.98% increase from the previous average price target of $81.50.

Diving into Analyst Ratings: An In-Depth Exploration

The standing of Hologic among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hologic compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Hologic's stock. This comparison reveals trends in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Hologic's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Hologic analyst ratings.

Discovering Hologic: A Closer Look

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

A Deep Dive into Hologic's Financials

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Challenges: Hologic's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -5.69%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Hologic's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.33% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Hologic's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.1% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Hologic's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.8%, the company showcases efficient use of assets and strong financial health.

Debt Management: Hologic's debt-to-equity ratio is below the industry average at 0.55, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: What Are They?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.